Biography
Sascha Rutz is a Principal Scientist in the Cancer Immunology Department at Genentech. He is the Research Lead for the T Cell Therapy program in Oncology at Genentech, focused on developing TCR-engineered T cells targeting neoantigens in solid tumors. Sascha is a T cell immunologist by training, and received his Ph.D. from Humboldt University Berlin, Germany, before joining Genentech as a Postdoc in 2009.

Biography
Dr. Elliot Norry has served as Chief Medical Officer of Adaptimmune since January 2020 and he is a member of the Executive Team. Previously, Dr. Norry was Vice President of Clinical Safety in Pharmacovigilance at Adaptimmune, and leader of their ADP- A2AFP program. Prior to joining Adaptimmune, Dr. Norry served as Safety Development Leader at GSK, where he managed clinical safety for a broad range of early and late-stage products, including improvement activities for pazopanib for the treatment of soft tissue sarcoma. He was also chair of GSK’s Hepatic Safety Panel. Prior to his roles in the biotech and pharmaceutical industry, Dr. Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania. He holds a B.A. from Columbia College and an M.D. from New York University. He performed his residency in Internal Medicine at Temple University Hospital in Philadelphia and his fellowships in gastroenterology at Thomas Jefferson University Hospital in Philadelphia.

Biography
Prior to joining Lyell, Dr. Albertson was Vice President of Global Drug Development at Juno Therapeutics, a Bristol-Myers Squibb company. Before Juno, Dr. Albertson served as Medical Director at Seagen. Dr. Albertson also completed a pediatric oncology fellowship at University of Washington. Dr. Albertson received a Ph.D. in Cancer Biology from University of Washington, an M.D. from Stanford University, and a B.S. in Biology from University of Oregon.

Biography
Hy Levitsky is President of Research and Development. He was previously EVP and CSO at Juno Therapeutics, and before that, Head of Cancer Immunotherapy Experimental Medicine at Roche Pharma Research and Early Development. He received an MD from Johns Hopkins School of Medicine in 1984, followed by training in internal medicine and medical oncology. He joined the Johns Hopkins faculty in 1991, rising to Professor of Oncology, Medicine and Urology in 2001 while working at the Sidney Kimmel Comprehensive Cancer Center where he served as Scientific Director of the George Santos Bone Marrow Transplant Program. Upon joining industry, he has held an adjunct professorship since 2011. His research has focused on tumor immunology, cancer vaccines, and adoptive T cell therapy. He is a Leukemia and Lymphoma Society Stohlman Scholar, a Member of the American Society for Clinical Investigation, and is a founding member of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Biography
Susie leads medical sciences at Arsenal Bio, a programmable cell therapy company, #engineeredtocure, that develops integrated circuit T cell (ICT) therapies for the treatment of solid tumors. She is a physician, scientist, and biopharma executive with over 20 years of experience leading clinical and translational research dedicated to improving patients' lives and finding a cure for cancer. Prior to joining Arsenal Bio, Susie was at Allogene developing allogeneic CAR T cell therapies. Throughout her career, she has worked on novel treatments for solid and hematologic malignancies across modalities including biologics, small molecules, antibody-drug conjugates and bispecific T-cell engagers. Susie has held senior leadership roles at Abbvie, Gilead and Amgen, and is a founding member of the Chicago chapter of Chief, an organization dedicated to supporting, empowering, and mentoring women C-suite leaders.